Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2011 1
2012 2
2013 2
2014 3
2015 1
2016 1
2017 2
2018 7
2019 8
2020 9
2021 11
2022 8
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
Basket Trials for Intractable Cancer.
Qin BD, Jiao XD, Liu K, Wu Y, He X, Liu J, Qin WX, Wang Z, Zang YS. Qin BD, et al. Among authors: zang ys. Front Oncol. 2019 Apr 12;9:229. doi: 10.3389/fonc.2019.00229. eCollection 2019. Front Oncol. 2019. PMID: 31032221 Free PMC article. Review.
Gout-associated lung disease.
Zang YS, Fang Z, Li B. Zang YS, et al. Rheumatology (Oxford). 2012 Apr;51(4):756. doi: 10.1093/rheumatology/ker354. Epub 2011 Nov 28. Rheumatology (Oxford). 2012. PMID: 22123991 No abstract available.
E3 ligase MKRN3 is a tumor suppressor regulating PABPC1 ubiquitination in non-small cell lung cancer.
Li K, Zheng X, Tang H, Zang YS, Zeng C, Liu X, Shen Y, Pang Y, Wang S, Xie F, Lu X, Luo Y, Li Z, Bi W, Jia X, Huang T, Wei R, Huang K, Chen Z, Zhu Q, He Y, Zhang M, Gu Z, Xiao Y, Zhang X, Fletcher JA, Wang Y. Li K, et al. Among authors: zang ys. J Exp Med. 2021 Aug 2;218(8):e20210151. doi: 10.1084/jem.20210151. Epub 2021 Jun 18. J Exp Med. 2021. PMID: 34143182 Free PMC article.
Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway).
Jiao XD, Qin BD, Wang Z, Liu K, Wu Y, Ling Y, Qin WX, Wang MM, Yuan LY, Barreto SG, Kim AW, Mak K, Li H, Xu YY, Qiu XM, Wu M, Jin M, Xu LC, Zhong Y, Yang H, Chen XQ, Zeng Y, Shi J, Zhu WY, Ding QQ, Jia W, Liu SF, Zhou JJ, Shen H, Yao SH, Guo ZJ, Li T, Zhou PJ, Dong XW, Lu WF, Coleman RL, Akce M, Akladios C, Puccetti F, Zang YS. Jiao XD, et al. Among authors: zang ys. Front Oncol. 2023 Feb 23;13:860711. doi: 10.3389/fonc.2023.860711. eCollection 2023. Front Oncol. 2023. PMID: 36910668 Free PMC article.
56 results